The renal denervation product developer secured more than $20m in a round that included strategic investor BrosMed Medical.

Vascular intervention technology provider BrosMed Medical took part in a series B-plus round for Brattea, a China-based developer of renal denervation (RDN) medical technology, on Tuesday sized at over $20m. Healthcare-focused private equity fund Kuanping Capital led the round, which also featured Hengxu Capital, Pudong Science & Technology Investment, Northern Light Venture Capital, BioTrack Capital…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.